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A B S T R A C T
The aim of this article is to illustrate the principal challenges, from the medical and technical point of view, associated
with the use of ultrahigh field (UHF) scanners in the clinical setting and to present available solutions to circumvent these
limitations.
We would like to show the differences between UHF scanners and those used routinely in clinical practice, the principal advantages,
and disadvantages, the different UHFs that are ready be applied to routine clinical practice such as susceptibility-weighted
imaging, fluid-attenuated inversion recovery, 3-dimensional time of flight, magnetization-prepared rapid acquisition gradient
echo, magnetization-prepared 2 rapid acquisition gradient echo, and diffusion-weighted imaging, the technical principles of
these sequences, and the particularities of advanced techniques such as diffusion tensor imaging, spectroscopy, and functional
imaging at 7TMR.
Finally, the main clinical applications in the field of the neuroradiology are discussed and the side effects are reported.
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Introduction
In the last decade, advances in medical imaging have revo-
lutionized the diagnosis and treatment of diseases of the cen-
tral and peripheral nervous systems. The introduction of high-
strength magnetic field (3 tesla) in magnetic resonance imaging
(MRI) has allowed the visualization of small structures in ex-
ceptional detail.
7 T MR is the next natural step in the clinical setting;
however, it is not currently widely used yet. Only sixty-one
7 T MRI scanners are in function around the world.1 Few
centers have begun to use this technique that has been lim-
ited to selected patients with certain pathologies such as mul-
tiple sclerosis (MS),2 epilepsy,3 tumors,4,5 to evaluate the ef-
fects of radiotherapy on normal appearing brain in patient with
gliomas,4 neurodegenerative diseases, and vascular pathologies
(Fig 1).4,6
A higher static magnetic field strength offers various advan-
tages for in vivo applications such as increased signal-to-noise
ratio (SNR),7,8 which can be translated to higher spatial res-
olution for structural and functional MR,3,9 increased chemi-
cal shift dispersion,10 and improved sensitivity in T2*-weighted
blood oxygenation-level-dependent (BOLD) imaging.11 Mag-
netic susceptibility-weighted techniques also benefit from ultra-
high field (UHF) strength imaging as it allows visualization of
small anatomical structures based on susceptibility differences
between blood, iron, and myelin.
On the other hand, increased main magnetic field inhomo-
geneity, B1 inhomogeneity, and artifacts represent new chal-
lenges.
In this review, we aim to illustrate the sequences that
are ready at UHF to be applied to routine clinical practice,
new artifacts, some of the challenges inherent to UHF, and a
more accurate assessment of metabolites by MR spectroscopy
(MRS).
Clinical Applications
The anatomical regions most likely to benefit fromUHF are the
central nervous and musculoskeletal systems. This is due to the
fact that structures in these systems are relatively unaffected by
cardiac and breathing motion, which allows us to use sequences
with higher spatial resolution that need a longer acquisition
time.
For the brain, the principal clinical applications are related
to the high resolution with which anatomical structures can
be depicted,1,2 improved contrast, reduced quantity of contrast
medium used, and new sequences that are likely to be devel-
oped in the future5 (Fig 2).
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Fig 1. Axial susceptibility-weighted imaging (TR 28 milliseconds, TE 20 milliseconds, flip angle 10, voxel size .4 × .4 × 1 mm, acquisition
time 5 minutes) nicely illustrates the small, irregular, and enlarged vessels in this patient with a capillary telangiectasia of the frontal lobe (A,
arrows). A zoomed image (B) shows a remarkable depiction of the normal transmedullary veins on both sides of the cerebral hemispheres.
Fig 2. Axial and coronal high-resolution magnetization-prepared two rapid acquisition gradient echo (TR 6000 milliseconds, TE 3.1 millisec-
onds, IT 1,800 milliseconds, IT2 2,700 milliseconds, .6 mm isotropic resolution, acquisition time 10 minutes) of a 28-year-old volunteer. Note
the excellent delineation of the different components of the basal ganglia in (A) and (B). Full coverage of the brain in (C). Note also the high
contrast between gray and white matter in (A) to (C).
The pathologies that could benefit from 7 T MRI include
MS,2,12–15 tumors,5 epilepsy3 (Figs 3a, 3b, 4, 5), neurodegener-
ative, and vascular diseases and those that require functional
imaging.4
The high anatomical resolution can be used to obtain higher
precision in the planning of electrode positioning in the treat-
ment of Parkinson disease and epilepsy or in the ablation of
tumors.1
Seven tesla imaging will provide a better understanding of
the pathophysiology of different types of tumors, in part, due to
improved identification and characterization of low-grade and
high-grade areas of infiltration, the interface between edema
and tumor, and changes in tumor permeability,5 particularly
with the help of susceptibility imaging, which should directly
impact on tumor classification and planning of treatment (better
identification of biopsy targets).16
This will furthermore help understand tumor response and
side effects of treatment. In epilepsy, the detection and char-
acterization of subtle lesions can be of critical importance for
patient management, especially for patients who suffer from
medically refractory epilepsy and are candidates for surgery.
Indeed, the detection of a structural lesion largely increases the
odds of favorable postoperative seizure control, by guiding re-
section or the placement of intracranial electrodes for invasive
monitoring.
Seven tesla imaging can guide treatment as it is currently
possible to visualize the hippocampi and their microstructure;
different articles illustrate various anatomical structures such as
the subiculum and Cornu Ammonis (CA), CA1, CA2, CA3,
and CA4 (Figs 3a and 3b).16 Focal cortical dysplasia, the most
common cause of medically refractory epilepsy in children and
also frequent in adults, can also be very difficult to detect even
with 3 T imaging. Postoperative outcome is increased by to-
tal resection of the lesion. A better detection and delineation
of these lesions at 7 T would therefore be very useful. Small
posttraumatic lesions could also be better detected at 7 T.
UHF increases the detection rate and improves character-
ization of cortical, thalamic and leptomeningeal lesions, and
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Fig 3a. Coronal high-resolution T2 showing different regions of the
hippocampus. Note the exceptional differentiation between white and
gray matter. 1. Hippocampal head. 2. Gyrus dentatus. 3. Uncal sul-
cus. 4. Cornu Ammonis. (CA)1, 5. CA2 3, 6. CA4. TH = temporal
horn; PH = parahippocampal gyrus.
their contribution to cognitive decline in MS.12,13 Magnetic sus-
ceptibility sequences allow visualization of small caliber blood
vessels at the center of white matter lesions and they improve
visualization of lesions of the cervical and upper dorsal spine
cord due to high spatial resolution.14,15,17
Furthermore, magnetic susceptibility imaging can play a key
role in identifying patients at risk of bleeding, for example, those
with arteriovenous malformations in which treatment is contro-
versial and also to determine the risk of rupture of aneurysms
by studying the vascular wall.18
Adverse Effects
Side effects of UHF-MRI include vertigo, the main complaint
at UHF according to Theysohn et al,19 followed by nausea,
light flashes, metallic taste in the mouth, too much noise during
image acquisition, and discomfort. De Vocht et al reported a
decreased performance on cognitive tests with no effects per-
ceived on the working memory.20 Furthermore, no significant
changes in vital signs have been demonstrated.21
Acquisition time is still a real limitation; gradient recalled
echo (GRE)-based sequences such as magnetization-prepared
rapid acquisition gradient echo (MPRAGE), magnetization-
prepared 2 rapid acquisition gradient echo (MP2RAGE), or
SPoiled Gradient Recalling imaging (SPGR) allow a full cover-
age of the brain in a reasonable time for clinical applications.
Applications of spin echo (SE)-based sequences, however, have
several limitations due to specific absorption rate (SAR) con-
strains that limit the number of slices available per unit of time.
In order to achieve a reasonable acquisition time for clinical
examination, small spatial coverage in the slice direction is ob-
tained. However, remarkable image quality can be obtained in
brain regions defined beforehand by other means such as elec-
troencephalogram (EEG), clinical information, or other MRI
sequences.
The higher spatial resolutions that are possible at UHF in-
crease scan time as a result, which can result in patient discom-
fort. Additionally, it may be necessary to extend measurement
time due to the higher SAR at field strengths of 7 T, which is a
problem particularly for sequences comprising high radio fre-
quency (RF) power pulses, such as T2-weighted imaging (WI)
spin echo or fluid-attenuated inversion recovery (FLAIR) using
turbo spin echo/fast spin echo (TSE/FSE) readout. Multiarray
coils in combination with parallel imaging can accelerate the ac-
quisition resulting in reasonable scan times for clinical studies.
Furthermore, new methods were developed lately to overcome
Fig 3b. Sagittal magnetization-prepared two rapid acquisition gradient echo image shows different regions of the hippocampus. Note the ex-
ceptional differentiation between white and gray matter. 1. Hippocampal head. 2. Temporal horn. 3. Subiculum. 4. Uncal sulcus. 5. Hippocampal
body. 6. Hippocampal tail. 7. Alveus. 8. Gyrus dentatus.
Fig 4. A 20-year-old patient known for focal epilepsy due to bilateral fronto-parietal and temporal polymicrogyria. (A) shows polymicrogyria
on sagittal 3-dimensional T1 at 3 T. In (B) and (C), the magnetization-prepared 2 rapid acquisition gradient echo sequence at 7 T clearly shows
a much better delineation of polymicrogyria due to improved contrast between gray and white matter.
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Fig 5. A 24-year-old patient with tuberous sclerosis. Subependymal nodules are well visualized as hypointense round abnormalities adjacent
to the right lateral ventricle (*) on axial susceptibility-weighted imaging. Zoomed image (B) shows a vein in contact with the nodule (arrows)
almost invisible on axial spin echo T1 at 3 T with contrast.
SAR limitation for TSE implementation. For instance, reduc-
tion of SAR level on 2-dimensional TSE can be achieved using
gradient and spin echo (GRASE) or RF subpulses.22,23 Three-
dimensional T2-weighted sequences are also promising;24 how-
ever, these different methods are not yet sufficiently developed
to be used in clinical routine.
Anatomical models have been utilized to calculate the in-
duced current density and SAR in adults, children, pregnant
woman, and fetuses. The effects change with age, the tissues
most affected in adults and children by the high SAR being
cerebrospinal fluid (CSF), the skin, and gray matter.25
The use of UHF is difficult in children as side effects are
particularly difficult to tolerate in this age group. There is only
one report in the literature dedicated to 7 T MRI in children
and no studies have proven the complete safety of this type of
exam if performed repeatedly.
Sequences
Images acquired on 7 T scanners have incomparable spa-
tial resolution and definition, particularly those produced by
susceptibility-weighted imaging (SWI). Although the funda-
mental architecture of sequences used at 7 T is the same as on
3 T scanners (MPRAGE, MP2RAGE, SPGR, SE T2, FLAIR,
SWI, diffusion tensor imaging [DTI], 3-dimensional time of
flight [TOF], and spectroscopy), significant improvements and
parameter adjustments are still necessary to bring 7 T MRI
into routine clinical practice. The most common sequences
currently used in clinical practice and issues relating to opti-
mization of these sequences are dealt with in the next section.
T1 Weighted
The most common technique for acquiring T1-weighted im-
ages at 7 T is the MPRAGE sequence. Despite being widely
used at 3 T, at higher field strength, MPRAGE images are in-
homogeneous due to B1 variations, which may impair clinical
interpretation. One approach is to use two inversion times (ITs)
(MP2RAGE), which has the advantage of producing bias-free
images with high contrast between gray and white matter in
addition to a robust T1 mapping (Figs 2 and 3b, and 4).26
Fluid-Attenuated Inversion Recovery
FLAIR is a pulse sequence that nulls tissue or fluid signal by
applying an inversion pulse before signal acquisition. By care-
fully choosing the IT, the signal from any particular tissue can
be canceled; in clinical MR, it is mostly used to suppress CSF.
FLAIR is used to detect/diagnose a wide range of central
nervous systemdiseases and offers an increased sensitivitywhen
compared to T1 and T2 images in the evaluation of stroke,
MS, infection, and toxic and metabolic diseases. T2-weighted
FLAIR imaging is currently one of the cornerstones of MR
neuroimaging protocols in the clinical setting at 1.5 and 3 T.27
The contrast of gray/white matter does not necessarily in-
crease with the field strength.28 This is due to the length-
ening of T1-values of gray and white matter at UHF, while
the T1 of CSF is relatively field-independent, leading to com-
promised T2-contrast and reduced magnetization recovery at
the moment of excitation. To overcome this problem, a UHF
version of FLAIR was developed comprising a magnetization
preparation module that effectively leads to an inversion re-
covery of the CSF but only to a saturation of gray and white
matter.29
Diffusion-Weighted Imaging and Diffusion Tensor Imaging
Diffusion-weighted imaging (DWI) allows the noninvasive vi-
sualization of anatomical connections between different parts of
the brain by mapping the diffusion process of water molecules
8 Journal of Neuroimaging Vol 28 No 1 January/February 2018
in biological tissues. The first diffusion MRI images were pro-
duced in the mid-1980s and were used soon after in the clinical
setting.
Diffusion and DTI are widely used in the field of neurora-
diology for the study and to guide treatment of diseases such
as stroke, infections, etc. DTI is particularly successful because
it reveals the brain connectivity and abnormalities/lesions in
white matter fiber structure. Diffusion images, tractography,
and more specifically fractional anisotropy profit greatly of a
higher magnetic field where the resolution is paramount. How-
ever, increased distortion by field inhomogeneity at UHF re-
mains a challenge that needs to be overcome in order to fully
benefit from the UHF potential.30 Some new approaches are
being explored such as readout-segmented echo planar imag-
ing (EPI) together with motion correction showing promising
results.31,32
Susceptibility-Weighted Imaging
SWI is an MRI technique that exploits the local magnetic
field differences between tissues.33,34 SWI is based on a fully
flow-compensated 3D high-spatial resolution GRE that com-
bines magnitude and unwrapped phase images to produce an
enhanced contrast magnitude image. By increasing the field
strength, it enables the use of shorter echo times (TE) while
maintaining the same phase difference, and along with a higher
SNR, it improves resolution and speed.1,35
Unfortunately, the field patterns seen in phase images are
nonlocal due to small local susceptibility distributions. Thus,
the phase images do not necessarily reflect anatomical struc-
tures locally and the contrast depends on the orientation of
the object in relation to the main magnetic field.36 Care must
therefore be taken when relating the phase contrast (PC) to
brain anatomy, especially in regions of complicated anatomy
such as the basal ganglia. Quantitative susceptibility mapping
(QSM) overcomes this problem and might therefore replace
SWI at UHF even in clinical settings, despite the technical and
mathematical challenges.37
Currently, the most common indications are for the detec-
tion of microhemorrhages, calcifications, iron accumulation,
and the visualization of vascular structures, particularly veins38
(Figs 1 and 5).
3D TOF Angiography
Three-dimensional TOF is obtained routinely with clinicalMRI
at 1.5 and 3 T for detection of thrombus, plaques of atheroma,
vasculitis, and aneurysms at high resolution with a coverage of
10 cm and a resolution of .3 × .3 × .5 mm3.
At UHF, technical parameters are: FOV 200 × 190 ×
50 mm3 in transverse orientation and acquired voxel size .25 ×
.3 × .4 mm.
Recent studies have illustrated the benefits of 7 T in the
analysis of intracranial vessels with and without contrast,39 al-
lowing the visualization of the whole circle of Willis and in-
tracranial perforating arteries. However, venous contamina-
tion has been reported with both techniques.40,41 Brain cov-
erage is reduced by constraints of SAR and can result in
long acquisition times that are difficult to apply in clinical
routine.6
Finally, the new sequence MPRAGE-MRA seems to de-
crease the acquisition time with higher resolution.42
1H Magnetic Resonance Spectroscopy
1H MRS allows the noninvasive measurement of neurochemi-
cal information in the human brain. With the increase of mag-
netic field strength7 T, high spectral resolution (eg, improved
separation of glutamate and glutamine) and SNR would largely
improve the quantification for metabolites, reduce acquisition
time, and increase spatial resolution43 (Figs 6 and 7). However,
there are a number of technical challenges such as increased
B0, B1 field inhomogeneities (discussed below in the “chal-
lenges/solutions” section), chemical shift displacement (CSD)
due to volume selection, reduced T2 relaxation times, and in-
creased T1 relaxation times.
Individual metabolites actually experience different excita-
tion volumes due to their difference in chemical shift.
Despite the potential of UHF in spectroscopy, few clinical
applications have been reported and include the localization
of the epileptogenic zone in medically refractory epilepsy and
tumor lesions. The fact that higher field strength yields better
SNR and improved spectral resolution allows better metabolite
depiction. In epilepsy, the added value of UHF is the possibility
to measure glutamate and glutamine separately and also more
accurate assessment of gamma-amino butyric acid (GABA),
which can bring new insights into the detection of epileptic
lesions. For tumor assessment, improved spatial resolution may
improve the differentiation of edema from low-grade infiltration
and also characterization of lesions.44
Functional MRI
Noninvasive mapping of functional brain functions can be
achieved by functional MRI (fMRI) that allows the detection
of hemodynamic changes associated with cerebral activity. The
most standard method is the BOLD effect depending on the
paramagnetic properties of deoxyhemoglobin that induce local
modifications of the magnetic susceptibility.45
BOLD signal sensitivity increases linearly with field strength
opening the possibility to critically enhance spatial resolution
or to decrease the number of repetitions to obtain significant
BOLD changes at UHF.46,47 Furthermore, the intravascular
contribution from large vessels to BOLD signal decreases with
magnetic field strength offering a better spatial specificity at
higher field by reducing the signal from draining veins.48
These significant benefits in BOLD signal sensitivity and
specificity at UHF make clinical fMRI at 7 T the technique of
choice for non-invasive mapping of language or motor cortex
to be preserved during surgery.49 In patients with medically
refractory epilepsy, presurgical mapping can be enriched by
simultaneous EEG-fMRI that can be performed safely at 7 T
in order to noninvasively localize hemodynamic correlates of
interictal epileptic activity during presurgical investigations.3
Coils
The excellence of UHFMR imaging quality depends ultimately
on RF coil performance. The increase in the static magnetic
fields brings new physical challenges: decreased RF penetration
in a subject,7,50 higher RF power requirements,51 and increase in
susceptibility artifacts.52 Even more importantly, the RF wave-
length in the body becomes comparable or smaller in size than
the anatomical dimensions, which can lead to interference pat-
terns. While destructive interference leads to darkening of the
image, constructive interference may lead to local brightening
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Fig 6. (A) Left: transverse MR image of a brain with the selected volume of interest (VOI) for spectroscopic imaging indicated by the
blue square; Middle: enlarged spectra maps in VOI; Right: representative spectra from a voxel containing gray matter and white matter,
respectively (red boxes in the middle image). (B) Maps of relative concentrations to total creatine (tCr) (echo time/repetition time = 16/4,000
milliseconds, field of view = 190 × 190 mm2, VOI = 70 × 70 mm2, slice thickness = 10 mm, matrix = 20 × 20, number of excitations = 1,
interpolate = 32 × 32, elliptical k-space sampling, nominal resolution = 9.5 × 9.5 × 10 mm3). NAA = N-acetylaspartate; Cr = creatine; PCr =
phosphocreatine; Lac= lactate; GABA= gamma-amino butyric acid; GSH= glutathione; GPC= glycerophosphocholine; TAU= taurine; INS=
myo-inositol; PE = phosphoethanolamine; ASP = aspartate; Glu = glutamate; Gin = glutamina; Glx = Glutamate-Glutamine; NAAG = N-
Acetylaspartylglutamate. Numbers on the graph express the resonant frequencies in parts per million (ppm).
of the image. Therefore, at UHF MR imaging, a strong con-
tribution of the induced conductive and dielectric currents to
RF-induced signal variations across the subject is highly visible.
Compared to more conventional 3 T MR systems, achiev-
able B1 (transient B1) fields are also limited by less powerful
RF power amplifiers (2 A˚-15 kW at 3 T, compared to 2 A˚-4 kW
at 7 T) and inherently higher cable losses. This results in a situ-
ation where RF power demanding sequences such as spin echo
sequences face challenges with respect to sufficiently available
B1 and imaging speed due to increased RF heating concerns in
the body.
UHF enables improved sensitivity and encoding capabilities
of fMRI. The introduction of multiple receiver arrays showed
the sensitivity benefit of receiving the MR signal with multiple
smaller coils.53 Reduced acquisition times are not only favor-
able in reducing the impact of subject motion, but also allow
functional measurements in the same subject and in the same
measurement session, which is ideal for studying the relation
between anatomy and function.
Acquiring whole-brain T2-weighted images at 7 T is chal-
lenging due to both visible inhomogeneous transmit patterns in
the image and power deposition limitations. However, combin-
ing parallel transmit methods with SAR and scan time reducing
approaches may overcome this problem.54
Another challenge at UHF head imaging is tissue heating,
which is a result of time-varying magnetic-field-induced elec-
tric fields in a subject according to Maxwell’s equations. The
electric field induces currents in a subject, which leads to tis-
sue heating in the case of a conductive tissue. SAR limit rel-
evant to the UHF imaging RF coils is 10 W/kg for averaged
over 10 g of tissue according to IEC 60601-2-33 (IEC, 2010)
guidelines.
A crucial goal in increasing the main field strength is to
achieve molecular-level high resolution to understand the brain
further. Currently, the sensitivity of available RF coils is limited
for microscopic imaging without administration of a contrast
agent to a subject. Molecular-level imaging is possible only
with the application of a specialized molecular sensor.55
10 Journal of Neuroimaging Vol 28 No 1 January/February 2018
Fig 7. In vivo 1H MR spectrum acquired using semiadiabatic SPE-
CIAL localization sequence (TE/TR = 12/7,500 milliseconds, 32 av-
erages) from a volume of interest (20 × 15 × 20 mm3) in the oc-
cipital lobe of a healthy volunteer and its LC model fit, fit residual,
and the individual metabolite fits. Lac = lactate; GABA = gamma-
amino butyric acid; NAA = N-acetylaspartate; Glu = glutamate;
Gln = glutamine; Asp = aspartate; Cr = creatine; PCr = phos-
phocreatine; GPC = glycerophosphocholine; Tau = taurine; Ins =
myo-inositol; GSH = glutathione; PCho = phosphocholine; NAAG
= N-Acetylaspartylglutamate; PE = phosphoethanolamine; Mac =
macromolecule baseline. Numbers on the graph express the reso-
nant frequencies in parts per million (ppm).
Challenges/Solutions
Current use of UHF MR imaging is limited by technical is-
sues including inhomogeneities of both the main magnetic field
(B0) and the applied RF field (B1), the SAR, and changes
in relaxation times compared to lower field strengths. These
limitations cause image artifacts, limit temporal and spatial
resolution and/or coverage, and restrict the use of MR spec-
troscopy. Solutions for these technical issues include parallel
transmit techniques and customized RF pulse sequences to pro-
duce a uniform transmission while minimizing deposited RF
energy (SAR) or parallel imaging to reduce the scanning time.
Inhomogeneities
All sequences should benefit from the increased SNR. How-
ever, when moving toward UHF, inhomogeneities appear in
the B0 and B1 fields.56
Both image geometry and intensity of signal are distorted
with B0 inhomogeneities, which increase linearly with the field
strength. For MR spectroscopy, inhomogeneous B0 field may
result in shifting and broadening of the spectral lines of metabo-
lites, leading to insufficient water and lipid saturation and degra-
dation in SNR and spectral separation.
Currently, automatic corrections are fully integrated in the
prescan procedure and are available in most commercially
available MR systems. Automatic shimming methods include
AUTOSHIM,57 FASTMAP,58 and are the most used clinically.
Anothermain challenge at 7 T is B1 inhomogeneities leading
to artificial signal differences across the brain for all common
MR contrasts and it is most severe for T2-weighted sequences,
such as SE and TSE. The most significant change is between
the overexposed area in the center of the brain and the pe-
riphery. For MRS, B1 inhomogeneities can lead to insufficient
peak power for the surface region of the brain, imperfections
of the excitation/refocusing slice profile, and the excitation of
unwanted signal originating outside the volume to interest.
These variations in B1 occur because RF wavelength ap-
proaches the size of the body part being imaged (head, chest,
and abdomen), therefore causing interferences. This leads to a
loss of signal and unexpected changes in contrast in anatomical
and spectroscopic images, which may ultimately result in the
misinterpretation of results. The use of parallel transmitters,59
barium titanium-based dielectric pads,60,61 and specific RF pulse
design have been proposed to mitigate the B1 inhomogeneity
occurring at high field strength.62
Specific Absorption Rate
Tissue heating caused by the absorption of radio waves is an-
other important challenge. RF power deposition, measured
as the SAR, increases exponentially with the magnetic field
strength. Although, in practice, some other aspects may help
counterbalance this problem, SAR restrictions are more limit-
ing compared to lower field strengths, requiring a reduction in
the number, duration, and amplitude of applied RF pulses in a
given time period.4
In pulse sequences that use many high flip angle RF pulses,
such as fast/turbo spin-echo and FLAIR, the SAR limit is
quickly reached.63 The first option to avoid an increasing SAR
is by distributing the flip angles over a larger time period (longer
TR), but in a clinical setting, time is a costly resource. Parallel
imaging combined with a lower flip angle schedule can be used
to reduce the acquisition time.64
Adapted RF pulse design (modification in frequency and
in amplitude/phase of the B1+ field) can minimize and some-
times settle the hardware/physical limitations so that gain in
signal intensity of UHF is available. The implementation of adi-
abatic pulses, which are less sensitive to B1 field variations, and
lower flip angles can reduce the SAR by keeping the same time
schedule.65 Tailored RF pulses are designed to cancel B1 varia-
tions by maintaining the same flip angle throughout the FOV.66
Nonselective tailored RF pulses (kT-points) were recently used
to obtain T2-weighted images with uniform contrast throughout
the whole brain.67
Relaxation Time Variation
Relaxation times change with the field strength: T1 values
increase along with the field strength and then converge to
a specific tissue-dependent value. T2* values decrease with
field strength, leading to a loss of signal but enhancing the
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sensitivity to deoxygenated blood and iron deposits. For spin-
echo sequences, apparent T2 values also shortened due to diffu-
sion effects through small local gradient variations in capillaries
that depend on the tissue type. T2 values also decrease but
the reduction is dependent on the type of tissue (gray/white
matter).68
Heuristic equations of the changes of T1 and T2* for cortical
gray matter are given here.4
A method to maximize the signal intensity would be to have
a longer time to repeat (TR) and shorter time to echo (TE).
A fundamental problem inherent to FLAIR imaging is the
lengthening of T1 constants of gray and white matter, while the
T1 of CSF is field-independent. This has two detrimental effects.
First, the desired T2 contrast is compromised, as the prolonged
T1 values significantly increase T1 weighting in FLAIR images
that counterbalances the T2 weighting. Second, the gain in SNR
is suboptimal, as part of the gain in magnetization obtained by
the increased field strength is lost by the reduced magnetization
recovery at the moment of excitation.
Conclusion
Seven tesla MRI scanners produce images with exceptional
SNR, high contrast, and unprecedented spatial resolution.How-
ever, several adjustments are indispensable in order tominimize
image artifacts mainly caused by inhomogeneities of both B0
and B1 fields. High spatial resolution is often associated with
larger imagingmatrices and ultimately longer scan times, which
are sometimes further extended by stricter SAR limits. There-
fore, reducing image acquisition time and consequently improv-
ing patient comfort is another challenge that must be overcome
in order to allow the future use of this type of scanner in the
clinical setting.
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